登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600981证券简称：汇鸿集团 公告编号：2025-042 江苏汇鸿国际集团股份有限公司关于 变更公司名称、证券简称及修订《公司章程》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 公司名称拟变更为：江苏苏豪汇鸿集团股份有限公司 ● 公司英文名称拟变更为：Jiangsu Soho High Hope Group Corporation ● 公司证券简称拟变更为：苏豪汇鸿，证券代码"600981"保持不变。 江苏汇鸿国际集团股份有限公司（以下简称"公司"）于2025年8月15日召开第十届董事会第三十八次会 议，以6票同意、0票反对、0票弃权，审议通过了《关于变更公司名称、证券简称及修订〈公司章程〉 的议案》。公司拟将中文名称"江苏汇鸿国际集团股份有限公司"变更为"江苏苏豪汇鸿集团股份有限公 司"，英文名称"Jiangsu High Hope International Group Corporation"变更为"Jiangsu Soho Hi ...

Group 1 - The board of directors of Luoxin Pharmaceutical Group Co., Ltd. held its 27th meeting, which was legally convened and attended by all five directors [1] - The board approved a proposal to provide a guarantee of RMB 20 million for its subsidiary, Luoxin Anruowei Pharmaceutical (Chengdu) Co., Ltd., to support its operational and business expansion needs [1] - The guarantee will be valid for 12 months from the date of approval by the shareholders' meeting [1] Group 2 - The board proposed to convene the fourth extraordinary general meeting of shareholders in 2025 on August 18, 2025, which also received unanimous approval [2] - The proposal for the guarantee and the extraordinary general meeting will require approval from at least two-thirds of the voting rights at the shareholders' meeting [2]

Group 1 - The company held its eighth board meeting of 2025 on June 5, 2025, with all nine directors participating, complying with relevant laws and regulations [1][2] - The board approved a proposal to provide financing guarantees for seven wholly-owned subsidiaries, with a total guarantee amount not exceeding USD 1 billion from July 1, 2025, to June 30, 2026 [1][2] - The board also approved a proposal to apply for the registration and issuance of medium-term notes with a total scale not exceeding RMB 5 billion, pending shareholder approval [2] - The company plans to hold its 2024 annual general meeting on June 30, 2025, with the board secretary authorized to prepare specific details [2][3]

Group 1 - The company plans to issue new shares on the Shanghai Stock Exchange, with the resolution valid from the approval date of the 2024 annual general meeting until the 2025 annual general meeting [2] - The board of directors is authorized to handle all matters related to the issuance of shares, including the preparation and submission of relevant documents, determining the issuance plan, and managing the use of raised funds [2][3] - The issuance plan is subject to approval by the 2024 annual general meeting and must comply with relevant laws and regulations [3] Group 2 - The company has proposed an adjustment to the independent directors' remuneration, increasing it from RMB 52,000 to RMB 65,000 per year, pending approval at the 2024 annual general meeting [5][6] - This adjustment aims to enhance the motivation of independent directors and align their compensation with their responsibilities and the company's operational status [6] Group 3 - The company intends to use idle self-owned funds for cash management, with a maximum investment amount of RMB 400 million in short-term, low-risk financial products [10][11] - The investment aims to improve the efficiency of the company's idle funds while ensuring daily operational needs and fund safety [11][17] - The board has authorized the chairman to make investment decisions within the specified limits [14] Group 4 - The company has decided to abolish the supervisory board, transferring its powers to the audit committee of the board, and will revise the articles of association accordingly [19][20] - This change is in compliance with the revised Company Law and aims to streamline governance [19] Group 5 - The 2024 annual general meeting is scheduled for May 8, 2025, with both on-site and online voting options available for shareholders [22][23] - The meeting will address various proposals that have been approved by the board, including those requiring special resolutions and those involving related party transactions [25]